BRIEF-EMA'S PRAC extends safety review of chronic Hep C treatments

* Started review of diabetes medicine canagliflozin after increase in amputations in ongoing trial
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.